MetasTx
MetasTx
Categories
Biotechnology
About
The scientific foundation of MetasTx’s breakthrough work is based on decades of research focused on p21 activated kinase (PAK-1). This enzyme is well-known to be pivotal in cancer initiation and metastasis and is highly expressed in Prostate, Breast, and Skin cancers.
MetasTx is developing a pipeline of novel cancer agents targeted at specific solid tumors based on advances in the delivery of IPA-3, a highly selective inhibitor of Group-1 P21 activated kinases (PAK).
An estimated 608,570 Americans died from cancer in 2021. The five-year survival rate of metastatic cancers, those that travel from the primary site to a distant site (also known as Stage 4 or 5), is approximately 30%.
This area of research is ripe for advances. Unfortunately, current drug discovery in metastatic cancer has not resulted in therapies with significant increases in patient survival, specificity in drug delivery, or mitigation of deleterious side effects; Until now.
Get Updates
from LSPA
Stay up-to-date on the latest news and events from Life Sciences PA, insights from the life sciences industry, and so much more!
Life Sciences Pennsylvania was founded in 1989 by a biotech scientist at Penn State University. Today it has grown to represent the entire life sciences industry – medical device companies, pharmaceutical companies, investment organizations, research institutions, and myriad service industries that support the life sciences in Pennsylvania.